AR067322A1 - Vector poxvirus recombinante de mapache (rrcnv) vacuna felina, plasmido y metodos para inducir una respuesta inmune protectora a un patogeno de felino en un gato - Google Patents

Vector poxvirus recombinante de mapache (rrcnv) vacuna felina, plasmido y metodos para inducir una respuesta inmune protectora a un patogeno de felino en un gato

Info

Publication number
AR067322A1
AR067322A1 ARP080102317A ARP080102317A AR067322A1 AR 067322 A1 AR067322 A1 AR 067322A1 AR P080102317 A ARP080102317 A AR P080102317A AR P080102317 A ARP080102317 A AR P080102317A AR 067322 A1 AR067322 A1 AR 067322A1
Authority
AR
Argentina
Prior art keywords
feline
cat
recombinant poxvirus
recombinant
mapache
Prior art date
Application number
ARP080102317A
Other languages
English (en)
Inventor
Michael A Gill
Hsien-Jue Chu
Stephen Qitu Wu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR067322A1 publication Critical patent/AR067322A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Vectores de poxvirus recombinantes de mapache que comprenden dos o más moléculas de ácido nucleico exogenas, que codifica cada una por lo menos una proteína de felino, en donde por lo menos dos de las moléculas de ácido nucleico se insertan en el sitio de hemaglutinina (ha) o el sitio de timidina quinasa (tk), o por lo menos una de las moléculas de ácido nucleico se inserta en cada uno de los sitios de hemaglutinina y timidina quinasa. Las vacunas recombinantes de felino, monovalentes y polivalentes comprenden una cantidad inmunologicamente efectiva de los vectores de poxvirus recombinantes de mapache y. opcionalmente, un vehículo o diluyente adecuado. La vacuna incluye opcionalmente antígenos de felino adicionales para suministrar proteccion de amplio espectro a gatos contra una variedad de patogenos de felino. Se induce una respuesta inmune protectora a los patogenos de felino en un gato al administrar las vacunas recombinantes.
ARP080102317A 2007-05-30 2008-06-02 Vector poxvirus recombinante de mapache (rrcnv) vacuna felina, plasmido y metodos para inducir una respuesta inmune protectora a un patogeno de felino en un gato AR067322A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93241907P 2007-05-30 2007-05-30

Publications (1)

Publication Number Publication Date
AR067322A1 true AR067322A1 (es) 2009-10-07

Family

ID=39701101

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102317A AR067322A1 (es) 2007-05-30 2008-06-02 Vector poxvirus recombinante de mapache (rrcnv) vacuna felina, plasmido y metodos para inducir una respuesta inmune protectora a un patogeno de felino en un gato

Country Status (13)

Country Link
US (1) US20080299149A1 (es)
EP (1) EP2155883A1 (es)
JP (1) JP2010528603A (es)
KR (1) KR20100038323A (es)
CN (1) CN101849013A (es)
AR (1) AR067322A1 (es)
AU (1) AU2008260593A1 (es)
CA (1) CA2681183A1 (es)
CL (1) CL2008001558A1 (es)
CO (1) CO6241172A2 (es)
MX (1) MX2009013030A (es)
WO (1) WO2008150404A1 (es)
ZA (1) ZA200908963B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX344103B (es) * 2010-08-31 2016-12-05 Merial Ltd Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
SI2734230T1 (sl) 2011-07-20 2019-04-30 Merial Limited Rekombinantno cepivo proti virusu mačje levkemije, ki vsebuje optimiziran gen ovojnice virusa mačje levkemije
US11229699B2 (en) * 2017-11-06 2022-01-25 Intervet Inc. Feline calicivirus vaccine

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3944469A (en) * 1974-11-21 1976-03-16 Pitman-Moore, Inc. Feline calicivirus vaccine and production thereof
US4264587A (en) * 1979-08-01 1981-04-28 Pedersen Niels C Vaccine for preventing persistent feline leukemia viremia in cats
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5106619A (en) * 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
US5374424A (en) * 1986-10-03 1994-12-20 Miles Inc. Multivalent felv-infected feline vaccine
US5242686A (en) * 1990-11-07 1993-09-07 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
US6004563A (en) * 1990-11-07 1999-12-21 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
US6241989B1 (en) * 1991-07-09 2001-06-05 Cornell Research Foundation, Inc. Recombinant multivalent viral vaccine
US7087234B1 (en) * 1991-07-09 2006-08-08 Cornell Research Foundation, Inc. Recombinant multivalent viral vaccine
US6010703A (en) * 1993-07-26 2000-01-04 Board Of Trustees Operating Michigan State University Recombinant poxvirus vaccine against feline rhinotracheitis
TW377373B (en) * 1993-09-22 1999-12-21 Wyeth Corp Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US5972350A (en) * 1996-05-06 1999-10-26 Bayer Corporation Feline vaccines containing Chlamydia psittaci and method for making the same
JP4000608B2 (ja) * 1996-11-07 2007-10-31 トヨタ自動車株式会社 水素製造充填装置および電気自動車
US6231863B1 (en) * 1997-06-10 2001-05-15 American Cyanamid Company DNA sequences, molecules, vectors and vaccines for feline calicivirus disease and methods for producing and using same
US6051239A (en) * 1997-10-20 2000-04-18 Thomas Jefferson University Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
US6106841A (en) * 1998-02-04 2000-08-22 Heska Corporation Delivery method for recombinant raccoon poxvirus
US6534066B1 (en) * 1999-07-16 2003-03-18 Merial Inactivated vaccine against feline calicivirosis
US6541458B1 (en) * 1999-07-16 2003-04-01 Merial Feline calicivirus genes and vaccines in particular recombinant vaccines
AU2003236646B2 (en) * 2002-05-16 2009-01-15 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
US7309495B2 (en) * 2003-03-14 2007-12-18 The Regents Of The University Of California Hemorrhagic feline calicivirus
US7306807B2 (en) * 2004-09-13 2007-12-11 Wyeth Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease

Also Published As

Publication number Publication date
EP2155883A1 (en) 2010-02-24
JP2010528603A (ja) 2010-08-26
WO2008150404A1 (en) 2008-12-11
KR20100038323A (ko) 2010-04-14
MX2009013030A (es) 2010-03-25
AU2008260593A1 (en) 2008-12-11
US20080299149A1 (en) 2008-12-04
ZA200908963B (en) 2010-08-25
CA2681183A1 (en) 2008-12-11
CO6241172A2 (es) 2011-01-20
CN101849013A (zh) 2010-09-29
CL2008001558A1 (es) 2008-07-25

Similar Documents

Publication Publication Date Title
ATE461710T1 (de) Nipah-virus-impfstoffe
BRPI0512421A (pt) recombinantes de avipox expressando genes do vìrus da doença febre aftosa
BRPI0923599A2 (pt) vírus da febre suína clássica recombinante, vacina para febre suína clássica viva, métodos para proteger um animal contra a febre suína clássica, para diferenciar animais infectados com o vírus da febre suína clássica de animais não infectados ou de animais vacinados com a vacina para febre suína clássica, e para isolar um vírus da febre suína clássica recombinante infeccioso, molécula de cdna, uso do vírus da febre suína clássica recombinante infeccioso, e, elisa com base em peptídeo
CY1113540T1 (el) Εμβολια γριππης σκυλων
AR060565A1 (es) Vacuna para la gripe aviaria y metodos de uso
CR9551A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
BR112015005987A2 (pt) vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína
CO6140071A2 (es) Poxvirus de mapache que expresa glicoproteinas de la rabia
Sadler et al. Evaluation of two canine distemper virus vaccines in captive tigers (Panthera tigris)
WO2008083239A3 (en) Compositions and methods for stimulating an immune response
BR112015002131A8 (pt) Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante
PE20211545A1 (es) Dosis unitaria de vacuna contra el dengue y administracion de esta
BR112015017966A2 (pt) composições imunogênicas compreendendo vírus silificado e métodos de uso
BR112018006567A2 (pt) vacinas de partículas semelhantes a vírus (vlp) do parvovirus canino (cpv) e seus usos
CL2017003224A1 (es) Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante
BR112014001409A2 (pt) métodos e composições para vacinação contra staphylococcus aureus
AR067322A1 (es) Vector poxvirus recombinante de mapache (rrcnv) vacuna felina, plasmido y metodos para inducir una respuesta inmune protectora a un patogeno de felino en un gato
RS52705B (en) Administration of FeLV Vaccine Without Needle
BR112023019301A2 (pt) Formulações de vacina de coronavírus
AR051636A1 (es) Vacunas multivalentes para la gripe aviar
AR047581A1 (es) Vacunas de calicivirus felino
AR094810A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna
BR112012014624A2 (pt) suspensão homogênea de compostos de imunopotenciação e usos dos destes
ATE529131T1 (de) Impfung mittels gezielter transkutaner freisetzung
PH12014501688A1 (en) Influenza c virus and vaccine

Legal Events

Date Code Title Description
FA Abandonment or withdrawal